Ophthalmology

Eye
#Clinical trials #Comment #Covid-19 #Eye #Eye health #Ophthalmology

New narrated podcast on ophthalmology

This is the latest episode of the free DDW podcast, “A deep dive into the future of ophthalmology”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Innovation, investment and commitment: Genentech’s approach to the future of ophthalmology” and “… Read More

#News

#AAV #Cell and gene therapy #Drug delivery #Gene delivery #Gene therapy #mRNA #Nanomedicine / nanotechnology #Ophthalmology

Lipid nanoparticles and mRNA used to treat hereditary blindness

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition.  Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. … Read More

#News #Trending News

Uveal melanoma
#Cancer research #FDA #iOnctura #Ophthalmology #Orphan drugs #United States

FDA grants orphan drug status for uveal melanoma drug

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma.  Uveal melanoma is a disease in which cancer originates in the tissues of the eye, causing symptoms such as blurred vision or a… Read More

#Cancer Research #News #Regulatory

Cancer research
#Cancer immunotherapy #Cancer research #Funding #Immunotherapy #Investment #ISA Pharmaceuticals #Oncology #Ophthalmology #Synthetic biology

$5 million to fund trial of therapy for uveal melanoma

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More

#Business & Investment #Cancer Research #News

Diabetic macular oedema
#Biopharmaceuticals #Diabetes #Ophthalmology #Phase II trial #Rezolute

Oral therapy for diabetic macular oedema progresses to Phase II

Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO).   The current standard of care for DMO is anti-vascular growth factor (anti-VEGF) injections into the eye,… Read More

#News

Patient with dry eye disease using eye drops
#Dry eye #FDA #Ophthalmology #Phase III trial #Stem cells

Stem cell dry eye therapy could offer rapid and total relief

The US Food and Drug Administration (FDA) has approved the Phase III clinical trial design for BRIM Biotechnology’s lead candidate for dry eye disease (DED), BRM421. BRIM will submit the Phase III study protocol to the FDA later this year.  BRM421 is a novel, first-in-class regenerative peptide therapy which, if… Read More

#News #Regulatory

#ALS #Alzheimer's #Biomarkers #Breast cancer #Cell and gene therapy #Head and neck cancer #Ice Bucket Challenge #Manufacturing #Neurodegenerative disorders #Oncology #Ophthalmology

This week in drug discovery (3-7 October)

News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and… Read More

#News

Retinitis pigmentosa
#American Academy of Ophthalmology 2022 #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology #Retinitis pigmentosa

Janssen shares ‘encouraging’ gene therapy study results

Results from Phase I/II MGT009 study into investigational gene therapy botaretigene sparoparvovec suggest sustained vision improvement in patients with X-linked retinitis pigmentosa (XLRP).  The study found treatment with botaretigene sparoparvovec had an acceptable safety profile and demonstrated encouraging improvements in retinal sensitivity, visual function and functional… Read More

#News

#Asia #Ophthalmology #Regulatory

Visus signs deal with Zhaoke to develop eye-drops across Asia  

Clinical-stage pharmaceutical company Visus Therapeutics has signed a licensing agreement for the development and commercialisation of its pupil-modulating eye drops with Zhaoke Ophthalmology.  Under the terms of the agreement, Zhaoke will be responsible for clinical development, regulatory approval and commercialisation of Visus’ Brimochol PF and Carbachol PF… Read More

#News

#Drug discovery #Eye health #iPSC #Ophthalmology #Partnership

Evotec enters ophthalmology drug discovery partnership 

Evotec has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (iPSC)-based disease modelling for ophthalmologic disorders.   Context   Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. … Read More

#News